KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Leases (2017 - 2025)

Amneal Pharmaceuticals has reported Current Leases over the past 9 years, most recently at $2.7 million for Q4 2025.

  • Quarterly results put Current Leases at $2.7 million for Q4 2025, down 15.76% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (down 15.76% YoY), and the annual figure for FY2025 was $2.7 million, down 15.76%.
  • Current Leases for Q4 2025 was $2.7 million at Amneal Pharmaceuticals, down from $3.5 million in the prior quarter.
  • Over the last five years, Current Leases for AMRX hit a ceiling of $10.1 million in Q2 2022 and a floor of $2.6 million in Q3 2021.
  • Median Current Leases over the past 5 years was $3.4 million (2025), compared with a mean of $5.8 million.
  • Biggest five-year swings in Current Leases: tumbled 75.09% in 2021 and later surged 227.85% in 2022.
  • Amneal Pharmaceuticals' Current Leases stood at $2.6 million in 2021, then grew by 8.84% to $2.9 million in 2022, then skyrocketed by 220.91% to $9.2 million in 2023, then plummeted by 65.12% to $3.2 million in 2024, then decreased by 15.76% to $2.7 million in 2025.
  • The last three reported values for Current Leases were $2.7 million (Q4 2025), $3.5 million (Q3 2025), and $8.2 million (Q2 2025) per Business Quant data.